- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07949695
Neoadjuvant Trastuzumab Rezetecan Plus Toripalimab and Endocrine Therapy in HR-Positive HER2-Low Breast Cancer
An Exploratory Prospective Single-Arm Study of Trastuzumab Rezetecan Combined With Toripalimab and Endocrine Therapy as Neoadjuvant Treatment in Patients With Stage II-III HR-Positive, HER2-Low Primary Breast Cancer
This is a single-arm, prospective exploratory clinical study. The purpose of this study is to evaluate the efficacy and safety of trastuzumab rezetecan (SHR-A1811) combined with toripalimab and endocrine therapy as neoadjuvant treatment for patients with stage II-III HR-positive, HER2-low primary breast cancer.
Eligible participants will receive the combination neoadjuvant regimen before surgery. The primary endpoint is pathological complete response (pCR, ypT0/is ypN0) rate after surgery. Secondary endpoints include objective response rate (ORR), residual cancer burden (RCB), event-free survival (EFS), overall survival (OS), and safety.
A total of 30 participants will be enrolled. The recruitment period will last for 12 months. All enrolled subjects will receive study treatment and follow-up according to the study protocol.
연구 개요
상태
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Yongsheng Jia
- 전화번호: +86-18622199359
- 이메일: yongshengjia@tjmuch.com
연구 장소
-
-
-
Tianjin, 중국, 300060
- 모병
- Tianjin Medical University Cancer Institute and Hospital
-
연락하다:
- Yongsheng Jia
- 전화번호: +86-18622199359
- 이메일: yongshengjia@tjmuch.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Aged ≥18 and ≤70 years old.
- Histopathologically confirmed invasive breast cancer; no prior systemic anti-tumor therapy for breast cancer.
- Histopathologically confirmed HR-positive (ER >1%) and HER2-low breast cancer. HER2-low is defined as IHC 1+ or IHC 2+ with ISH-negative.
- Ki-67 proliferation index ≥30%.
- Stage II-III breast cancer per the 8th edition AJCC TNM staging criteria (cT2 N1-2 M0, or T3-4 N0-2 cM0).
- At least one measurable target lesion according to RECIST Version 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Female participants may be pre-menopausal, peri-menopausal or post-menopausal. Post-menopause is defined according to CSCO Breast Cancer Guidelines as any one of the following:
Bilateral oophorectomy;
- Age ≥ 60 years;
- Age < 60 years with spontaneous amenorrhea for ≥12 months; no chemotherapy, tamoxifen, toremifene or ovarian function suppression in the past 12 months, and post-menopausal levels of FSH and estradiol;
- Age < 60 years receiving tamoxifen or toremifene, with post-menopausal FSH and estradiol levels documented on two consecutive tests.
9、Adequate organ function (no blood product or growth-factor-supported correction within 14 days prior to first study drug administration):
- Hematologic function: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; platelets ≥ 100 × 10⁹/L; hemoglobin ≥ 90 g/L.
- Hepatic and renal function: Albumin ≥ 3.0 g/dL; total bilirubin ≤ 1.5 × ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; alkaline phosphatase ≤ 2.5 × ULN; blood urea nitrogen and serum creatinine ≤ 1.5 × ULN OR creatinine clearance ≥ 60 mL/min (calculated by Cockcroft-Gault formula).
- Coagulation: Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
- Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 50% assessed by echocardiogram (ECHO).
- Electrocardiogram: QTcF (Fridericia-corrected QT interval) ≤ 470 ms for female subjects.
10、For pre-menopausal women of child-bearing potential: serum pregnancy test negative within 7 days before initiation of study treatment; non-lactating. All enrolled female participants must use adequate barrier contraception throughout treatment and for 6 months after completion of study treatment.
11、Voluntarily agrees to participate, provides written informed consent, demonstrates good compliance and is willing to complete all study-related visits and procedures.
Exclusion Criteria:
- Breast cancer without histopathological confirmation.
- Bilateral breast cancer, inflammatory breast cancer or occult breast cancer.
- Prior anti-neoplastic therapy of any modality (chemotherapy, radiotherapy, targeted therapy, endocrine therapy, etc.). Definitive radiotherapy received within 4 weeks before first study drug dose, or palliative radiotherapy received within 2 weeks before first study drug dose.
- Concurrent receipt of any other anti-tumor therapy.
- History of other malignancies within the past 5 years, except for cured basal-cell skin carcinoma and carcinoma in situ of cervix.
- Participation in another investigational-drug clinical trial within 4 weeks prior to enrollment.
- Received immunosuppressive agents or systemic corticosteroids for immunosuppressive purposes (>10 mg/day prednisone equivalent) within 2 weeks before first study drug administration; nasal or inhaled corticosteroids are permitted.
- Administration of live or attenuated vaccines within 4 weeks prior to first study drug dose.
- Major surgery unrelated to breast cancer within 4 weeks before first study drug dose, or incomplete recovery from such surgery.
- Active autoimmune disease, or history of autoimmune disease prone to relapse (including but not limited to autoimmune hepatitis, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism; hypothyroidism controlled solely by hormone-replacement therapy is allowed). Subjects with skin disorders not requiring systemic therapy (vitiligo, psoriasis, alopecia), insulin-controlled type 1 diabetes, or childhood-onset asthma fully resolved without adult-time intervention may be enrolled. Asthma requiring bronchodilator intervention is excluded.
- History of immunodeficiency, including HIV-positive status, other acquired or congenital immunodeficiency, or history of organ transplantation.
- Uncontrolled or clinically significant cardiovascular-cerebrovascular disease. Any of the following occurring within 6 months prior to first dose: NYHA class III-IV congestive heart failure, myocardial infarction, cerebral infarction (lacunar infarction excluded), pulmonary embolism, unstable angina; arrhythmias requiring treatment at screening; primary cardiomyopathy (dilated, hypertrophic, arrhythmogenic right-ventricular, restrictive or unclassified cardiomyopathy); clinically significant history of QTc prolongation; second-degree type-II or third-degree atrioventricular block; female QTcF > 470 ms; atrial fibrillation (EHRA grade ≥ 2b); uncontrolled hypertension judged by investigator to make subject ineligible.
- Known or suspected interstitial pneumonia; moderate-to-severe pulmonary disease impairing respiratory function within 3 months before first dose that may confound detection/management of drug-related pulmonary toxicity, including idiopathic pulmonary fibrosis, organizing pneumonia / bronchiolitis obliterans, pulmonary embolism, severe asthma, severe COPD, obstructive/restrictive lung disease; autoimmune / connective-tissue / inflammatory diseases with pulmonary involvement (e.g. rheumatoid arthritis, Sjögren syndrome, sarcoidosis); prior total pneumonectomy.
- Active hepatitis B (HBsAg-positive with HBV-DNA ≥ 500 IU/mL), hepatitis C (HCV-antibody-positive with HCV-RNA above upper limit of normal), liver cirrhosis; severe infection requiring antibiotics, antiviral or antifungal therapy.
- Known inherited or acquired bleeding or thrombotic diathesis (e.g. hemophilia, coagulopathy).
- Known hypersensitivity or contraindications to study drugs or their excipients.
- Pregnant or lactating women; women of child-bearing potential with positive baseline serum pregnancy test; women of child-bearing potential unwilling to use effective contraception throughout the study period.
- Concomitant medical conditions that, in the investigator's judgment, would endanger subject safety or prevent completion of the study (including but not limited to uncontrolled severe hypertension, severe diabetes, active infection).
- Documented history of neurological or psychiatric disorders including epilepsy or dementia; or any other condition rendering the subject unsuitable for the study in the investigator's opinion.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Trastuzumab Rezetecan plus Toripalimab and Endocrine Therapy Neoadjuvant Treatment
|
Patients receive 6 cycles of neoadjuvant trastuzumab rezetecan (4.8 mg/kg IV Q3W) plus toripalimab (240 mg IV Q3W) plus daily endocrine therapy (SERM/AI ± OFS; OFS for pre/perimenopausal women), followed by surgery. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Pathological Complete Response Rate (pCR, ypT0/isN0)
기간: At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).
|
Percentage of patients achieving pathological complete response (pCR, defined as ypT0/isN0) in breast and axillary lymph nodes after neoadjuvant therapy, assessed by central pathology review after surgery |
At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Objective Response Rate (ORR)
기간: At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).
|
Percentage of patients with confirmed objective response (CR or PR) assessed by investigator according to RECIST criteria. |
At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).
|
|
Residual Cancer Burden (RCB)
기간: At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).
|
RCB class and continuous RCB score determined from surgical specimens after neoadjuvant treatment. |
At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).
|
|
Event-Free Survival (EFS)
기간: Up to 3 years after surgery
|
Time from enrollment to first occurrence of invasive breast cancer recurrence, distant metastasis, second primary malignancy, or death from any cause, whichever comes first. |
Up to 3 years after surgery
|
|
Overall Survival (OS)
기간: Up to 5 years after surgery
|
Time from enrollment to death from any cause. |
Up to 5 years after surgery
|
|
Safety
기간: From start of study treatment up to 30 days after last dose of study drugs
|
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) graded per CTCAE. |
From start of study treatment up to 30 days after last dose of study drugs
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Immune biomarkers (sTIL, PD-L1, etc.)
기간: Baseline and at surgery
|
Assessment of immune biomarkers including stromal tumor-infiltrating lymphocytes (sTIL) and PD-L1 expression in baseline tumor samples and post-treatment surgical specimens. |
Baseline and at surgery
|
|
Ki-67 expression
기간: Baseline and at surgery
|
Change in Ki-67 proliferation index between baseline biopsy and surgical specimens after neoadjuvant therapy. |
Baseline and at surgery
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- E20261415
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .